Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P18858

UPID:
DNLI1_HUMAN

ALTERNATIVE NAMES:
DNA ligase I; Polydeoxyribonucleotide synthase [ATP] 1

ALTERNATIVE UPACC:
P18858; B2RAI8; B4DTU4; Q2TB12; Q32P23

BACKGROUND:
The enzyme DNA ligase 1, with alternative names DNA ligase I and Polydeoxyribonucleotide synthase [ATP] 1, is integral to the DNA repair mechanism. It acts by sealing nicks in the double-stranded DNA during repair, replication, and recombination, thus preserving the genetic blueprint of life.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of DNA ligase 1 could open doors to potential therapeutic strategies. Its direct link to Immunodeficiency 96, a genetic disorder marked by severe immune system challenges, underscores the enzyme's significance in developing novel therapeutic approaches for immunodeficiency disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.